Gérard Zalcman, MD, PhD, on Managing NSCLC With Nivolumab and Ipilimumab: Updated Findings on Optimal Length of Treatment
Posted: Thursday, September 15, 2022
Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses findings on the merits of a shorter or longer course of treatment with nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer (NSCLC).
